• Link to Facebook
  • Link to X
  • Link to LinkedIn
  • Link to Youtube
  • Link to Mail
  • For Patients
  • Customer Login
  • Newsletter Sign-up
Profound Medical
  • Home
  • Physicians
    • Customizable Incision-Free Therapies
  • Technology
    • TULSA-PRO®
    • Sonalleve®
  • Company
    • About
    • Leadership Team
    • Board of Directors
    • Careers
  • Investors
    • Profile
    • Governance
    • Presentations
    • TACT Data
    • Webcasts
    • Financial
    • Press Releases
    • Analyst Coverage
    • Subscribe
  • Clinical Publications
    • Clinical Outcomes for Localized Prostate Cancer
    • Demonstrating Feasibility in other Prostate Disease States
    • Review Articles and Commentaries
    • Early Development
  • PRO-Talk Academy
  • Reimbursement
  • Contact
    • Accessibility
  • Menu Menu

Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

February 19, 2024/in Newswire/by Ben Block

TORONTO, March 01, 2023 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 9:10 a.m. Eastern Time.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:022024-02-19 13:28:02Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

February 19, 2024/in Newswire/by Ben Block

TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

February 19, 2024/in Newswire/by Ben Block

TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:20 p.m. GMT.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

Profound Medical Announces Third Quarter 2022 Financial Results

February 19, 2024/in Newswire/by Ben Block

TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Profound Medical Announces Third Quarter 2022 Financial Results

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

February 19, 2024/in Newswire/by Ben Block

TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 financial results after market close on Thursday, November 3, 2022.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer

February 19, 2024/in Newswire/by Ben Block

TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that updated results from the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study were presented for the first time this past weekend, on Saturday, September 24, 2022, by Laurence Klotz, M.D., FRCSC, CM, Professor of Surgery, University of Toronto and Sunnybrook Chair of Prostate Cancer Research, at the FOCAL 2022 Conference held in Los Angeles, CA.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

February 19, 2024/in Newswire/by Ben Block

TORONTO, Sept. 15, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced changes to its management team and structure designed to further position the Company for continued sales success and global growth.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

Profound Medical to Participate in September Investor Conferences

February 19, 2024/in Newswire/by Ben Block

TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in September.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Profound Medical to Participate in September Investor Conferences

Profound Medical Provides TULSA-PRO® Reimbursement Update

February 19, 2024/in Newswire/by Ben Block

TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S. reimbursement update for Transurethral Ultrasound Ablation (“TULSA”), performed with its TULSA-PRO® system.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Profound Medical Provides TULSA-PRO® Reimbursement Update

Profound Medical Announces Second Quarter 2022 Financial Results

February 19, 2024/in Newswire/by Ben Block

TORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png 0 0 Ben Block https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Ben Block2024-02-19 13:28:012024-02-19 13:28:01Profound Medical Announces Second Quarter 2022 Financial Results
Page 7 of 14«‹56789›»
Search Search

Recent Posts

  • Profound Medical Announces First Quarter 2025 Financial Results
  • Profound Medical Announces First Quarter 2025 Financial Results
  • Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
  • Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
  • Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Categories

  • Blog Post
  • CEO Update
  • Events
  • Frontpage Article
  • News
  • Newswire
  • Uncategorized
  • Whitepapers

Tags

CEO Message CONALLEVE Corona Corona Virus COVID-19 Erectile Dysfunction Erectile Function EUROPE FLA HIFU meeting PATIENT PROFOUND PROSTATE RELEASE SOFTWARE SONALLEVE TACT TDC tulsa TULSA-PRO TULSAPRO TULSAPROCEDURE tulsa procedure TULSA TREATMENT Webinar

Quick Links

  • Home
  • News
  • Patients
  • Physicians
  • Privacy Policy
  • Accessibility

Careers & Training

  • Careers
  • Customer Login
  • TULSA-PRO Training

Head Office

Profound Medical Corp.,
2400 Skymark Avenue,
Unit #6, Mississauga, ON  L4W 5K5, Canada

T: 647.476.1350 
F:
 647.847.3739
info@profoundmedical.com

 
© Copyright - Profound Medical 2025
  • Home
  • Physicians
  • TULSA PRO
  • Patients
  • Company
  • News
  • Investors
  • Contact
  • Customer Login
  • TULSA-PRO Training
  • Privacy Policy
Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn More

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only